At a Glance Commentary
======================

Scientific Knowledge on the Subject
-----------------------------------

Aspirin-exacerbated respiratory disease (AERD) is characterized by asthma, hypersensitivity to aspirin and other nonsteroidal antiinflammatory drugs, chronic rhinosinusitis, mast cell activation, and overproduction of cysteinyl leukotrienes. The management of AERD involves guideline-based treatments for asthma and chronic rhinosinusitis, and avoidance of all medications that inhibit cyclooxygenase-1. Although systemic corticosteroid treatment was reported to partially attenuate upper and lower respiratory tract symptoms after aspirin challenge in AERD, all types of antiasthma medication have failed to completely suppress aspirin hypersensitivity, which continues throughout the life span of patients.

What This Study Adds to the Field
---------------------------------

This study is the first double-blind, randomized, placebo-controlled, crossover study to evaluate the efficacy of omalizumab against the overproduction of leukotriene E~4~, aspirin hypersensitivity, and disease symptoms during an oral aspirin challenge in patients with AERD and at least one positive result in the specific IgE test for common environmental allergens. Omalizumab treatment suppressed overproduction of urinary leukotriene E~4~ and 11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid, which is a key feature of the pathogenesis of AERD, after an aspirin challenge. Furthermore, aspirin hypersensitivity disappeared in more than half of the patients after 3 months of omalizumab therapy, and serious eosinophilic airway inflammation and mast cell activation in AERD were effectively suppressed by omalizumab starting within 24 hours.

Aspirin-exacerbated respiratory disease (AERD) is characterized by severe asthma, hypersensitivity to aspirin and other nonsteroidal antiinflammatory drugs, chronic rhinosinusitis with nasal polyposis, and overproduction of cysteinyl leukotrienes ([@bib1]--[@bib4]). Although nonatopic AERD is common, a subset of patients develop elevated total serum IgE levels ([@bib5]). Pathologically, AERD is associated with mast cell activation ([@bib6]--[@bib8]) and serious eosinophilic inflammation in the respiratory mucosa ([@bib9]). The requirement for high-dose corticosteroids to control asthma and the frequent recurrence of chronic rhinosinusitis with nasal polyposis after surgery reflect the aggressive, persistent nature of the disease ([@bib1]--[@bib3]). Systemic corticosteroid therapy was shown to partially attenuate aspirin-induced airway symptoms in AERD, but did not completely suppress aspirin-hypersensitivity reactions to aspirin exposure ([@bib10]).

In AERD, aspirin hypersensitivity is usually lifelong, and accidental exposure to nonsteroidal antiinflammatory drugs causes subsequent life-threatening asthma exacerbations. However, no treatment completely suppresses aspirin-hypersensitivity reactions, except for aspirin desensitization ([@bib2], [@bib11]). Therefore, it is important to identify medications that strongly suppress hypersensitivity reactions after exposure to nonsteroidal antiinflammatory drugs ([@bib2], [@bib3], [@bib12], [@bib13]).

Omalizumab, a humanized recombinant monoclonal anti-IgE antibody, binds selectively to the IgE constant region to block free IgE binding to IgE receptors ([@bib14]--[@bib17]). Previous studies demonstrated the effectiveness of omalizumab for severe allergic asthma ([@bib15], [@bib17]--[@bib21]) and other allergic diseases ([@bib22]). Furthermore, omalizumab reduced high-affinity IgE Fc receptor expression on mast cells ([@bib23], [@bib24]), basophils ([@bib25], [@bib26]), and dendritic cells ([@bib27]), which may suppress their activation.

In a previous clinical observational study, we found that a 12-month treatment for AERD using omalizumab showed clinical effectiveness for upper and lower respiratory tract symptoms, and resulted in a marked reduction to near-normal levels of urinary leukotriene E~4~ (LTE~4~) and the prostaglandin D~2~ metabolite 9α,11β-prostaglandin F~2~, both of which when overproduced represent a steady-state feature of AERD ([@bib28]). Other case studies reported that patients with AERD who were successfully treated with omalizumab developed aspirin tolerance ([@bib29]). However, the efficacy of omalizumab against AERD, aspirin hypersensitivity, and overproduction of LTE~4~ after an aspirin challenge has not been investigated in a randomized manner. In addition, it is not clear at what time point after the initiation of omalizumab treatment clinical effectiveness is observed in patients with AERD. Based on these factors, we hypothesized that omalizumab would suppress the overproduction of LTE~4~ and clinical symptoms during an aspirin challenge in patients with AERD.

Our aim in this study was to evaluate the efficacy of omalizumab against the overproduction of LTE~4~ after an aspirin challenge, aspirin hypersensitivity, and severe upper and lower respiratory symptoms---all of which are characteristic features of AERD---using a randomized design (SOSA \[Sagamihara Omalizumab Treatment Strategy for AERD\]). We measured the levels of the urinary mediators LTE~4~ and 11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (tetranor-PGDM), the dominant cyclooxygenase product of mast cells ([@bib30]), during an oral aspirin challenge. Hypersensitivity symptoms during an oral aspirin challenge, inflammatory biomarkers, and asthma- and nasal-related symptoms were also evaluated in relation to omalizumab treatment.

Methods
=======

Study Design and Participants
-----------------------------

The study was a randomized, double-blind, single-center, placebo-controlled, crossover trial with two treatment phases of 3-month duration in patients with AERD ([Figure 1A](#fig1){ref-type="fig"}). An oral aspirin challenge was conducted at the end of each treatment phase. The Ethics Committee of the National Hospital Organization Sagamihara National Hospital (Sagamihara, Japan) approved the study protocol. Written informed consent was obtained from all patients. This study was registered with the University Hospital Medical Information Network (number UMIN000018777; <https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021562>) in Japan.

![(*A*) Study design. (*B*) Flow diagram. AERD = aspirin-exacerbated respiratory disease; F[e]{.smallcaps}~NO~ = fractional exhaled nitric oxide.](rccm.201906-1215OC_f1){#fig1}

Patients 20--79 years of age with AERD were recruited from the National Hospital Organization Sagamihara National Hospital between August 24, 2015 and December 15, 2016. The patients were required to be clinically stable before undergoing an oral aspirin challenge (at least twice) safely. Asthma was diagnosed according to the American Thoracic Society criteria ([@bib31]) by pulmonologists and allergists. In addition, AERD was diagnosed by a positive result for systemic aspirin challenge, based on a modified oral challenge protocol ([@bib32], [@bib33]) within the last 2 years before enrollment. Positive reactions were evaluated by a respiratory function test and/or clinical symptoms (nasal and/or extrapulmonary symptoms) (*see* Methods section in the online supplement). All patients had at least one positive result in the specific IgE test for common environmental allergens. Maintenance oral corticosteroids and other regular asthma treatments were unchanged for the duration of the study. Information regarding the inclusion and exclusion criteria for study patients, randomization, masking, and anti-IgE and placebo therapies are provided in the online supplement.

Study Outcomes
--------------

The primary endpoint was the difference in the area under the logarithm level of urinary biomarker concentration versus time curve (AUC~\[Before-24\ h\]~) of LTE~4~ between the placebo and omalizumab phases during an oral aspirin challenge, because the AUC reflects the overall production of LTE~4~ in response to exposure to systemic aspirin. The secondary endpoints included the differences in urinary concentrations of LTE~4~ ([@bib34]) and tetranor-PGDM ([@bib30]) during the treatment phase (when there was no aspirin exposure), and the AUC~(Before-24\ h)~ of tetranor-PGDM during oral aspirin challenge, blood samples (peripheral blood eosinophil counts, periostin \[[@bib35], [@bib36]\], eosinophilic cationic protein, tryptase, platelet activation markers \[[@bib37]\], cytokines, and chemokines), lung function (FEV~1~% predicted, FVC% predicted, forced expired flow between 25% and 75% of the volume expired, and fractional exhaled nitric oxide \[F[e]{.smallcaps}~NO~\]), Asthma Control Test (ACT) ([@bib38]), Asthma Control Questionnaire-6 (ACQ-6) ([@bib39]), Sino-Nasal Outcome Test-22 (SNOT-22) ([@bib40]), asthma- and nasal-related symptom scores (visual analog scale \[VAS\]), and Global Evaluation of Treatment Effectiveness (GETE) ([@bib20]). Adverse events and medication use and adherence were also assessed at every study visit.

Statistical Analyses
--------------------

The baseline characteristics of patients were described as follows: number and percentage for categorical variables and the median (interquartile range \[IQR\]) for continuous variables. To compare the effects of treatments, the McNemar test for categorical variables and the Wilcoxon signed-rank test were used. A *P* value \< 0.05 was considered statistically significant. Bonferroni corrections were applied to adjust for the impact of multiple comparisons. Our sample size estimate was based on a change in the logarithm level of urinary LTE~4~ concentration between before and after omalizumab treatment in our previous study ([@bib28]). The mean change before and after omalizumab treatment in the log-transformed urinary LTE~4~ concentration (pg/mg of creatinine) was −0.70 with an SD of 0.525, and the number of participants was calculated to be nine patients at a significance level of 0.05 (two-sided) and power of 90%. To account for not being able to evaluate many endpoints during the long-term study period (\>10 mo), and to perform at least two aspirin challenges in participants in stable condition in up to 40% of patients with AERD, we set an initial enrollment goal of 16 patients. Intent-to-treat data were analyzed unless otherwise indicated. All statistical analyses were performed using R version 3.2.4 ([@bib41]).

The AUC~\[Before-24\ h\]~ of LTE~4~ and tetranor-PGDM was calculated using the trapezoidal rule. The AUC using the trapezoidal rule was defined as follows:$$AUC = \sum\limits_{i = 1}^{4}\frac{\left( t_{i + 1} - t_{i} \right)\left( C_{i} + C_{i + 1} \right)}{2}$$where *t*~*i*~ (*i* = 1, 2, 3, 4, 5) is the observation time (Before, 3 h, 6 h, 9 h, and 24 h, respectively) and *C*~*i*~ is the logarithm level of LTE~4~ or tetranor-PGDM for each time point *t*~*i*~. To calculate the AUC, we assumed that Before equaled 0 h.

Results
=======

Patient Recruitment and Characteristics
---------------------------------------

Screening visits were arranged for 21 patients; 16 were randomized to therapy and five were excluded before randomization ([Figure 1B](#fig1){ref-type="fig"}). The first patient was screened on August 24, 2015 and the last patient was screened on December 15, 2016. All patients completed the study as planned. The clinical characteristics of the patients are shown in [Table 1](#tbl1){ref-type="table"}. The study population consisted of 16 patients (10 female and six male) with a median age of 53 years (IQR, 44.0--60.0 yr), a median asthma onset age of 43.0 years (IQR, 27.0--56.3 yr), and a median serum IgE level of 169.0 IU/ml (IQR, 45.5--482.8 IU/ml). The median dose of monthly omalizumab was 300 mg (IQR, 150--600 mg). Three of the 16 patients (18.8%) received omalizumab every 2 weeks. The participants in this study demonstrated good adherence to the asthma medications.

###### 

Baseline Characteristics of All Patients at the Initial Study Visit

  Characteristic                                                                   *N* = 16
  ---------------------------------------------------------------------- ----------------------------
  Age, yr                                                                     53.0 (44.0--60.0)
  Sex, F, *n* (%)                                                                 10 (62.5)
  Asthma onset age, yr                                                        43.0 (27.0--56.3)
  Body weight, kg                                                             56.4 (49.6--59.6)
  Body mass index, kg/m^2^                                                    21.4 (20.5--23.0)
  Smoking status, never/past/current, *n* (%)                             8 (50.0)/6 (37.5)/2 (12.5)
  Maintenance prednisolone, *n* (%)                                                3 (18.8)
  Oral prednisolone daily dose, mg/d, *n* = 3                                    2.5/2.5/7.0
  Inhaled corticosteroid, *n* (%)                                                  16 (100)
  Inhaled corticosteroid (fluticasone equivalent) dose, μg/d                655.0 (492.5--1,000.0)
  Maintenance long-acting β-agonist, *n* (%)                                       16 (100)
  Maintenance leukotriene receptor antagonist, *n* (%)                             16 (100)
  One or more exacerbations during 12 mo before enrollment, *n* (%)                3 (18.8)
  One or more hospitalizations during 12 mo before enrollment, *n* (%)              0 (0)
  Status of sinus surgery and polypectomy                                              
   History of sinus surgery and polypectomy, *n* (%)                               7 (43.8)
   Median number of lifetime nasal polyp surgeries                                0 (0--1.0)
   Median time since last nasal polyp surgery, yr                              5.0 (3.5--10.5)
  ACQ-6                                                                         0.8 (0.3--2.6)
  ACT                                                                         20.5 (14.5--24.5)
  Peripheral eosinophil count per microliter                                 370.0 (270.0--530.0)
  Total serum IgE, IU/ml                                                     169.0 (45.5--482.8)
  Omalizumab dose, mg/mo                                                        300 (150--600)
  FEV~1~% predicted                                                          104.4 (92.7--112.0)
  FEV~1~/FVC%                                                                 75.2 (69.6--78.5)
  FVC% predicted                                                             118.6 (111.2--128.0)
  FEF~25--75%~ (%)                                                            56.8 (43.5--70.7)
  F[e]{.smallcaps}~NO~, ppb                                                   22.0 (17.1--31.0)

*Definition of abbreviations*: ACQ-6 = Asthma Control Questionnaire-6; ACT = Asthma Control Test; FEF~25--75~ = forced expiratory flow, midexpiratory phase; F[e]{.smallcaps}~NO~ = fractional exhaled nitric oxide.

Data are presented as medians and interquartile ranges unless otherwise indicated.

AUC~(Before-24\ h)~ and Levels of Urinary LTE~4~ and Tetranor-PGDM Concentrations during Oral Aspirin Challenge
---------------------------------------------------------------------------------------------------------------

The primary outcome and difference in the AUC~(Before-24\ h)~ of urinary LTE~4~ concentration between the placebo and omalizumab phases during an oral aspirin challenge are shown in [Figure 2A](#fig2){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}. There was a significant reduction in the AUC~(Before-24\ h)~ of urinary LTE~4~ concentrations in the omalizumab phase (51.1 \[IQR, 44.5--59.8\]) compared with the placebo phase (80.8 \[IQR, 65.4--87.8\]) (*P* \< 0.001). In addition, there was a significant reduction in the AUC~(Before-24\ h)~ of urinary tetranor-PGDM concentrations, which was a secondary outcome, in the omalizumab phase (53.8 \[51.3--56.8\]) compared with the placebo phase (61.2 \[57.9--64.0\]) (*P* \< 0.0001) ([Figure 2B](#fig2){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}).

![Difference in the area under the logarithm level of urinary biomarker concentration versus time curve (AUC~(Before-24\ h)~) and levels of urinary LTE~4~ and tetranor-PGDM concentrations during oral aspirin challenge between the placebo and omalizumab phases. (*A*) AUC~\[Before-24\ h\]~ of LTE~4~. (*B*) AUC~\[Before-24\ h\]~ of tetranor-PGDM. (*C* and *D*) Time course of log-transformed levels of urinary LTE~4~ (*C*) and tetranor-PGDM (*D*) concentrations. Wilcoxon signed-rank test. \**P* \< 0.05 and \*\**P* \< 0.01. The log-transformed urinary LTE~4~ and tetranor-PGDM concentrations are expressed as medians and interquartile ranges. LTE~4~ = leukotriene E~4~; tetranor-PGDM = 11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid.](rccm.201906-1215OC_f2){#fig2}

###### 

Difference in the Area under the Logarithm Level of Urinary Biomarker Concentration versus Time Curve during Oral Aspirin Challenge

                   Placebo Phase (*N* = *16*)   Omalizumab Phase (*N* = *16*)   *P* Value
  --------------- ---------------------------- ------------------------------- -----------
  LTE~4~               80.8 (65.4--87.8)              51.1 (44.5--59.8)          \<0.001
  Tetranor-PGDM        61.2 (57.9--64.0)              53.8 (51.3--56.8)          \<0.001

*Definition of abbreviations*: LTE~4~ = leukotriene E~4~; tetranor-PGDM = 11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid.

Data are presented as medians and interquartile ranges. Significance testing was performed using the Wilcoxon signed-rank test.

[Figures 2C and 2D](#fig2){ref-type="fig"} show the time course of changes in the levels of urinary LTE~4~ and tetranor-PGDM concentrations during an oral aspirin challenge. The levels at each time point (3, 6, 9, and 24 h) after the oral aspirin challenge were significantly lower in the omalizumab phase than in the placebo phase.

Development of Aspirin Tolerance and Change in the Cumulative Provoking Aspirin Dose
------------------------------------------------------------------------------------

In the placebo phase, all patients showed a positive reaction to the oral aspirin challenge. The median cumulative provocation dose of aspirin in the placebo phase was 150 mg (IQR, 90--210 mg). Conversely, in the omalizumab phase, 10 of 16 patients (62.5%) did not show a positive reaction, even after the highest cumulative dose (930 mg) was administered (*P* = 0.004; [Table 3](#tbl3){ref-type="table"}), indicating that these patients developed aspirin tolerance. Of the six patients with a positive reaction, the cumulative dose in four of the six patients increased from 90 mg to 210 mg. However, this was unchanged in the other two patients. Tables E1 and E2 and Figure E1 in the online supplement show the differences in VAS for asthma- and nasal-related symptoms and the maximal decline in FEV~1~ during oral aspirin challenge. VAS was scored significantly better at all time points in the omalizumab phase than in the placebo phase (*see* Table E1 and Figure E1). In addition, changes in FEV~1~ during the oral aspirin challenge were significantly smaller in the omalizumab phase than in the placebo phase (*see* Table E2). Moreover, there were significant correlations between the treatment-related improvement in FEV~1~ and that in VAS scores for wheezing and cough during the aspirin challenge (data not shown).

###### 

Change in the Cumulative Provoking Aspirin Dose during an Oral Aspirin Challenge

                                                Cumulative Provoking Aspirin Dose  
  ----------------------------------- --- ---- ----------------------------------- ---------------------------------------
  Developed aspirin tolerance                                                      
  1                                    M   53                  90                   930[\*](#tblfn1){ref-type="table-fn"}
  2                                    F   67                  30                   930[\*](#tblfn1){ref-type="table-fn"}
  3                                    M   72                  210                  930[\*](#tblfn1){ref-type="table-fn"}
  4                                    M   53                  930                  930[\*](#tblfn1){ref-type="table-fn"}
  5                                    F   65                  450                  930[\*](#tblfn1){ref-type="table-fn"}
  6                                    F   57                  210                  930[\*](#tblfn1){ref-type="table-fn"}
  7                                    F   42                  90                   930[\*](#tblfn1){ref-type="table-fn"}
  8                                    M   60                  90                   930[\*](#tblfn1){ref-type="table-fn"}
  9                                    F   57                  210                  930[\*](#tblfn1){ref-type="table-fn"}
  10                                   M   44                  210                  930[\*](#tblfn1){ref-type="table-fn"}
  Did not develop aspirin tolerance                                                
  11                                   F   21                  90                                    210
  12                                   F   60                  210                                   210
  13                                   F   49                  90                                    210
  14                                   F   52                  210                                   210
  15                                   M   44                  90                                    210
  16                                   F   40                  90                                    210

Significance testing was performed using the McNemar test.

No symptoms were observed after the cumulative dose of aspirin (930 mg).

The baseline characteristics of patients who did or did not develop aspirin tolerance are presented in Tables E3 and E4. Patients who developed aspirin tolerance showed later asthma onset, as well as elevated peripheral blood platelet counts and serum levels of IL-22, compared with patients who did not develop aspirin tolerance. However, these associations were not observed after Bonferroni correction. Moreover, there was no association between the response to omalizumab treatment assessed by GETE and the development of aspirin tolerance (data not shown).

Time Course of Improved Symptoms
--------------------------------

According to the GETE, seven of 16 patients (43.8%) reported a response to treatment within 7 days after starting treatment, and this increased to 11 of 16 patients (68.8%) at Month 3 ([Figure 3A](#fig3){ref-type="fig"}). Interestingly, three of 16 patients (18.8%) reported a rapid improvement of symptoms within 1 day of omalizumab treatment. In contrast, only two of 16 patients (12.5%) were responders in the placebo phase ([Figure 3B](#fig3){ref-type="fig"}).

![(*A* and *B*) Cumulative response rate according to the Global Evaluation of Treatment Effectiveness scale in the omalizumab (*A*) and placebo (*B*) phases. (*C--E*) Scores from the Asthma Control Test (ACT) (*C*), Asthma Control Questionnaire-6 (ACQ-6) (*D*), and Sino-Nasal Outcome Test-22 (SNOT-22) (*E*) in the omalizumab and placebo phases. McNemar test; \**P* \< 0.05 and \*\**P* \< 0.01 compared with the placebo phase. Global Evaluation of Treatment Effectiveness was used to classify responders and nonresponders. Wilcoxon signed-rank test; ^†^*P* \< 0.05 and ^††^*P* \< 0.01 compared with the placebo phase. Circles (placebo phase) and squares (omalizumab phase) indicate median values, and bars indicate interquartile ranges.](rccm.201906-1215OC_f3){#fig3}

The ACT, ACQ-6, SNOT-22, and VAS scored significantly better at most visits in the omalizumab phase compared with the placebo phase (*see* [Figures 3](#fig3){ref-type="fig"} and E3, and Table E7). Statistically significant differences were first observed at Month 1 for ACQ-6 and SNOT-22, and at Month 2 for ACT. All differences remained statistically significant up to Month 3, although the differences in ACQ-6 and ACT were small, indicating they were not clinically important differences ([@bib42], [@bib43]). Regarding the VAS, statistically significant differences were first observed at Month 1 for asthma symptoms (dyspnea, wheezing, and cough) and at Month 2 for nasal symptoms (nasal congestion, anterior rhinorrhea, and anosmia). All remained statistically significant up to Month 3.

Urinary Concentrations of LTE~4~ and Tetranor-PGDM during the Treatment Phase
-----------------------------------------------------------------------------

Significantly lower levels of urinary concentrations of LTE~4~ and tetranor-PGDM in the omalizumab phase compared with the placebo phase were observed as early as Day 1 ([Figure 4](#fig4){ref-type="fig"} and [Table 4](#tbl4){ref-type="table"}), and the low levels of LTE~4~ were maintained until Month 3. Levels of tetranor-PGDM also tended to be lower in the omalizumab phase than in the placebo phase throughout the treatment period, although this did not reach statistical significance at Day 7, Month 2, or Month 3.

![(*A* and *B*) Difference in the levels of urinary LTE~4~ (*A*) and tetranor-PGDM (*B*) concentrations between the placebo and omalizumab phases. Wilcoxon signed-rank test; \**P* \< 0.05. Circles (placebo phase) and squares (omalizumab phase) indicate median values, and bars indicate interquartile ranges. LTE~4~ = leukotriene E~4~; tetranor-PGDM = 11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid.](rccm.201906-1215OC_f4){#fig4}

###### 

Difference of Each Urine and Blood Biomarker between Placebo and Omalizumab Phases

  Variable                                Placebo (*N = 16*)    Omalizumab (*N = 16*)   *P* Value
  ------------------------------------- ---------------------- ----------------------- -----------
  Urine biomarkers, log-transformed                                                          
   LTE~4~, pg/mg of creatinine                                                               
    Day 0                                   2.1 (2.0--2.8)         2.4 (2.1--2.6)         0.404
    Day 1                                   2.2 (2.1--2.8)         2.1 (2.0--2.4)         0.008
    Day 7                                   2.3 (2.1--2.7)         2.0 (1.8--2.3)         0.002
    Month 1                                 2.4 (2.1--2.8)         2.0 (1.8--2.2)         0.008
    Month 2                                 2.3 (2.2--3.0)         2.0 (1.9--2.2)         0.002
    Month 3                                 2.4 (2.2--2.8)         1.9 (1.8--2.1)        \<0.001
   Tetranor-PGDM, pg/mg of creatinine                                                  
    Day 0                                   2.4 (2.3--2.5)         2.5 (2.4--2.7)         0.376
    Day 1                                   2.3 (2.3--2.5)         2.2 (2.0--2.4)         0.021
    Day 7                                   2.5 (2.3--2.5)         2.3 (2.2--2.6)         0.821
    Month 1                                 2.4 (2.3--2.6)         2.2 (2.2--2.4)         0.016
    Month 2                                 2.4 (2.3--2.6)         2.4 (2.2--2.6)         0.300
    Month 3                                 2.5 (2.4--2.6)         2.4 (2.3--2.5)         0.051
  Blood biomarkers                                                                           
   Eosinophil count per microliter                                                           
    Day 0                                380.0 (287.5--457.5)   320.0 (257.5--482.5)      0.497
    Day 1                                355.0 (302.5--502.5)   395.0 (267.5--440.0)      0.536
    Day 7                                385.0 (292.5--475.0)   315.0 (187.5--430.0)      0.028
    Month 1                              400.0 (295.0--607.5)   275.0 (150.0--370.0)      0.006
    Month 2                              385.0 (297.5--562.5)   325.0 (172.5--372.5)      0.007
    Month 3                              335.0 (250.0--442.5)   220.0 (170.0--290.0)      0.026
   Periostin, ng/ml                                                                          
    Day 0                                113.5 (103.2--157.0)    111.0 (98.8--133.0)      0.934
    Day 1                                121.0 (97.8--146.0)    111.5 (104.8--131.2)      0.831
    Day 7                                126.0 (98.8--177.0)     105.5 (91.5--128.5)      0.004
    Month 1                              109.0 (98.0--160.2)     107.5 (92.8--119.0)      0.038
    Month 2                              133.5 (96.8--161.8)     94.5 (85.8--116.2)       0.001
    Month 3                              123.5 (100.5--137.0)    96.0 (86.8--113.0)       0.001
   Eosinophil cationic protein, μg/L                                                         
    Day 0                                  13.3 (9.6--17.9)       11.3 (6.3--13.4)        0.021
    Day 1                                  11.7 (7.5--15.0)       12.0 (5.0--14.9)        0.940
    Day 7                                  15.4 (7.8--20.9)       11.0 (4.9--13.3)        0.039
    Month 1                                12.8 (7.5--16.2)        9.3 (6.1--14.1)        0.376
    Month 2                               16.2 (11.6--18.2)        9.6 (5.9--13.7)        0.039
    Month 3                                8.1 (5.6--15.0)         7.3 (5.4--10.4)        0.083
   Tryptase, μg/L                                                                            
    Day 0                                   3.4 (2.7--5.1)         3.1 (2.4--4.0)         0.049
    Day 1                                   3.1 (2.8--4.9)         3.1 (2.3--4.2)         0.696
    Day 7                                   3.1 (2.6--4.6)         2.9 (2.5--3.6)         0.022
    Month 1                                 3.1 (2.8--4.1)         3.0 (2.3--3.6)         0.009
    Month 2                                 3.0 (2.9--5.2)         2.8 (2.4--3.6)         0.140
    Month 3                                 3.1 (2.7--4.6)         2.9 (2.6--3.5)         0.003

*Definition of abbreviations*: LTE~4~ = leukotriene E~4~; tetranor-PGDM = 11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid.

Data are presented as medians and interquartile ranges. Significance testing was performed using the Wilcoxon signed-rank test.

Blood Biomarkers during the Treatment Phase
-------------------------------------------

Day 7 was the first day statistically significant differences were observed for peripheral blood eosinophil counts and serum periostin. All remained statistically significant until Month 3 (*see* Figure E2 and [Table 4](#tbl4){ref-type="table"}). The levels of serum eosinophilic cationic protein and tryptase were significantly lower at several time points in the omalizumab phase than in the placebo phase. In contrast, there were no significant differences in the platelet surface markers of free plasma platelets (CD62P and CD63) and the levels of soluble P-selectin between the placebo and omalizumab phases (*see* Table E5). The concentration of serum B-cell activating factor, a tumor necrosis factor family/B-lymphocyte stimulator member, was significantly increased in the omalizumab phase compared with the placebo phase (*see* Table E6), although this was not observed after Bonferroni correction.

Respiratory Functions and F[e]{.smallcaps}~NO~ during the Treatment Phase
-------------------------------------------------------------------------

All respiratory functions, except for FVC% predicted and F[e]{.smallcaps}~NO~, were significantly higher in the omalizumab phase than in the placebo phase (*see* Table E8). Regarding the forced oscillation technique, there were no significant differences in all parameters (respiratory system resistance and reactance) between the placebo and omalizumab phases (data not shown).

Safety and Adverse Events
-------------------------

Subcutaneous bleeding was reported as an adverse event in two patients (placebo phase, *n* = 0; omalizumab phase, *n* = 2). Two patients in the omalizumab phase reported injection-site erythema that was mostly mild. However, no moderate or severe adverse events related to omalizumab use, including generalized urticarial or anaphylaxis, were reported during the study period.

Discussion
==========

To the best of our knowledge, this is the first randomized, placebo-controlled trial to evaluate the efficacy of omalizumab against overproduction of LTE~4~, aspirin hypersensitivity, and upper and lower respiratory tract symptoms---all of which are important pathogenic factors in AERD---during an oral aspirin challenge. Omalizumab suppressed LTE~4~ and tetranor-PGDM overproduction during a systemic aspirin challenge, suggesting that omalizumab has inhibitory effects on mast cell function during an aspirin challenge, and therefore potentially during clinical adverse responses to aspirin. In addition, omalizumab significantly suppressed the urinary concentrations of LTE~4~ and tetranor-PGDM during treatment periods (when there was no aspirin exposure), suggesting that it has inhibitory effects on ongoing mast cell activation. Although no medication has been reported to completely suppress hypersensitivity symptoms after aspirin exposure ([@bib3], [@bib10]), 10 of 16 patients (62.5%) in our study became tolerant to aspirin under omalizumab treatment. These study findings indicate that omalizumab might be a potential orphan drug for AERD.

With regard to general asthma, the response to omalizumab was characterized by a progressive onset, and at least 12 weeks of omalizumab treatment was required before we could determine whether a satisfactory response had been achieved ([@bib15], [@bib44]). In contrast, in previous studies, early onset (within 1 d to 4 wk) of omalizumab efficacy was reported for most patients with chronic idiopathic urticaria/chronic spontaneous urticaria ([@bib45], [@bib46]). The findings of our study also demonstrated early onset of omalizumab efficacy: 3 of 16 patients (18.8%) reported rapid symptomatic improvement within 1 day of omalizumab treatment, and an additional 4 patients reported an improvement within 7 days. When early responders (*n* = 7, response until Day 7) were compared with late responders (*n* = 4, response after Month 1), the early responders tended to have more severe symptoms at baseline (Day 0) and showed a rapid improvement of the symptoms until Day 7 after starting treatment (data not shown). Symptoms after oral aspirin challenge were also suppressed relatively early: 10 of 16 patients (62.5%) developed aspirin tolerance after only 3 months of omalizumab treatment.

In our study, urinary LTE~4~ levels were significantly lower in the omalizumab phase than in the placebo phase as early as 1 day after initiation of treatment. In addition, peripheral eosinophil counts and serum periostin levels were significantly suppressed within 7 days of omalizumab treatment. These findings suggest that omalizumab can begin to effectively suppress serious eosinophilic airway inflammation and mast cell activation in AERD ([@bib1], [@bib7]--[@bib9]) within 24 hours, with the potential to improve aspirin hypersensitivity within 3 months. These findings were also supported by relatively rapid clinically significant improvements in GETE and each symptom score in the omalizumab phase compared with the placebo phase.

Previous studies suggested that omalizumab exerts its effects against general asthma by depleting free IgE and preventing the formation of an IgE/high-affinity IgE Fc receptor/mast cell axis ([@bib17], [@bib23], [@bib24]). A duration of \>10 weeks was reported to be required for the reduction of high-affinity IgE Fc receptors on mast cells ([@bib23]). However, recent *in vitro* studies demonstrated that omalizumab dissociated prebound IgE from its high-affinity IgE Fc receptor on mast cells, and that the inhibition of mast cells by omalizumab started rapidly, within 24 hours ([@bib47], [@bib48]). Increased levels of prostaglandin D~2~ in urine were reported in stable patients with AERD compared with patients with general asthma ([@bib1], [@bib8], [@bib49], [@bib50]). The early suppression of LTE~4~ and tetranor-PGDM overproduction by omalizumab during the treatment periods (when there was no aspirin exposure) observed in our study may be explained by its suppressive efficacy against ongoing, exposure-independent mast cell activation, which is an important pathogenetic feature of AERD ([@bib1], [@bib7]--[@bib9], [@bib50]). However, the mechanism of ongoing mast cell activation in AERD remains to be determined.

GETE is a subjective and single-item questionnaire that is completed by patients to determine the perceived effectiveness of a treatment before and after omalizumab treatment on a five-point categorical scale. The response scale is not centered on 0, or no change, because its three levels indicate a positive improvement and only one level definitively reflects a worse outcome. Therefore, although GETE simply measures perceived treatment effectiveness, it is commonly used in clinical trials of omalizumab therapy ([@bib14], [@bib20], [@bib51]). Of note, it was previously reported that GETE responses were similar between patients and investigators ([@bib20]).

The management of AERD involves guideline-based treatments for asthma and chronic rhinosinusitis and avoiding all medications that inhibit cyclooxygenase-1 ([@bib2], [@bib3], [@bib12]). However, patients with severe asthma require daily corticosteroid therapy and/or frequent steroid bursts to control their disease ([@bib1]--[@bib3]). Given the possible side effects of chronic corticosteroid therapy (e.g., osteoporosis, increased risk of infection, diabetes mellitus, weight gain, and adrenal suppression) ([@bib52]), the ability to taper or stop corticosteroid treatment is a major clinical benefit of omalizumab. In this study, no moderate-to-severe adverse events (e.g., anaphylaxis) or other clinically relevant adverse events were observed during the omalizumab phase.

This study has some limitations. First, it included a limited sample size of 16 patients, which was estimated before the start of the study, from a single center. Second, because this study was performed in Japanese patients with AERD, results from populations with other ethnic and genetic backgrounds were not available. Third, a selection bias toward patients with relatively mild AERD may have occurred. This is because patients with severe AERD who were preferentially enrolled in our previous observational study ([@bib28]) could not be enrolled in this randomized study because of previous omalizumab treatment (item 5 of the inclusion criteria). In addition, patients with severe AERD and uncontrolled asthmatic symptoms were not enrolled in this study because at least two safely performed oral aspirin challenges were required to evaluate the primary and secondary endpoints. Fourth, the possibility of prolonged carry-over effects could not be completely excluded because this was a randomized, crossover study. However, we extended the washout period to \>18 weeks to minimize this effect, and with regard to the levels of urinary LTE~4~ and tetranor-PGDM, there was no significant difference in the levels in the omalizumab preceding group at visit 1 (just before omalizumab treatment) and those at visit 7 (just before placebo treatment) (data not shown). This suggests that there were no prolonged carry-over effects in urinary biomarker concentrations. Fifth, no placebo for omalizumab was available from the manufacturer in this investigator-initiated trial. However, this is a minor limitation because the study endpoints were objective outcomes with minimal sensitivity to subjective bias. Finally, although both prostaglandin D~2~ and cysteinyl leukotrienes have been reported to promote the chemotaxis of group 2 innate lymphoid cells ([@bib53], [@bib54]), we did not evaluate the efficacy of omalizumab against group 2 innate lymphoid cells in this study. Investigators should consider these limitations when designing future studies.

In conclusion, this randomized study showed the efficacy of omalizumab against the overproduction of LTE4, mast cell activation, and the results of aspirin challenge in patients with AERD. Omalizumab treatment led to the development of aspirin tolerance and markedly reduced urinary LTE~4~ concentrations during an oral aspirin challenge. These findings indicate that omalizumab has efficacy against the key pathogenic features of AERD and might be an important therapeutic candidate for AERD.
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